Science

Remote-controlled insulin production

A new use for therapeutic nanoparticles in diabetes treatment

Remote-controlled insulin production

Researchers in New York have engineered a way to non-invasively trigger gene activation in live animals using nanoparticles and radio waves, a method that may, in the future, be used to remotely control genes in humans for medical purposes.

Current methods of activating cells are unwieldy at best: direct stimulation using electrodes is invasive, potentially damaging and non-specific, whilst control of individual light-activated channels using different wavelengths of precisely-timed light pulses requires internally implanted light pipes. But, by abusing the properties of iron oxide nanoparticles (FeNPs) and temperature-sensitive ion channels, the researchers found a way to finely control certain genes non-invasively.

Jeffery Friedman and colleagues of The Rockefeller University targeted FeNPs to a modified, temperature-sensitive cation channel, TRPV1 (otherwise known as the capsaicin receptor) by coating the nanoparticles with antibodies specific to a modified tag on the channel. Exposure to low- and mid-range radio wave frequencies heated up the targeted nanoparticles but not the surrounding tissue, thereby activating the channel upon reaching its activation temperature. The resulting calcium ion influx activated a specially modified gene that controlled expression of insulin. This lead to a corresponding drop in blood glucose levels after 30 minutes.

The team also experimented with nanoparticles that could be made intracellularly using modified ferritin, a naturally occurring iron-storage protein. They saw that insulin secretion still occurred, albeit more weakly.

Radio wave gene activation has the advantage of being both non-damaging to tissue and non-invasive whilst heating surrounding cells to a minimal degree. Currently however the technique can only be used in basic animal research, as the delivery of nanoparticles into a living organism requires the deliberate growth of tumours, making it inappropriate for use in human clinical research.

Friedman hopes though that as research progresses use of nanoparticles in a therapeutic setting will be able to treat diseases involving protein deficiencies, such as hexosaminidase A replacement in Tay-Sachs disease.

DOI: 10.1126/science.1216753

From Issue 1517

11th May 2012

Discover stories from this section and more in the list of contents

Explore the edition

Read more

How the Supreme Court ruling on gender is impacting queer people at Imperial

News

How the Supreme Court ruling on gender is impacting queer people at Imperial

Last month, the UK Supreme Court (UKSC) ruled that for the purposes of the Equality Act 2010 (EA 2010), the definition of a woman is based on biological sex.  The case brought before the court, For Women Scotland Ltd v The Scottish Ministers, asked if transgender women should be included

By Oscar Mitcham and Isabella Duchovny
College opens Imperial Global India in Bengaluru

News

College opens Imperial Global India in Bengaluru

Imperial College London has launched its fourth global hub in Bengaluru. The hub will host research programmes with Indian partners, focusing on some of “the world’s most pressing challenges in areas such as climate change and sustainability, food and water security, and antimicrobial resistance (AMR).” Launched at the Science

By Mohammad Majlisi